IA2030 Scorecard

 — 

Global

  • Type to select a Country

SP 6: Supply & Sustainability
6.1

Healthy global markets for vaccines

Level of health of the vaccine market—Global
Vaccine2019/202020212022
Bacille Calmette-Guerin (BCG)1
Unhealthy
Unhealthy
Healthy
Human papillomavirus (HPV)
Unhealthy
Concerning
Unhealthy
Pneumococcal conjugate vaccine (PCV)2
Concerning
Concerning
Healthy
Pneumococcal polysaccharide2
Concerning
Concerning
Not applicable
Measles
Concerning
Concerning
Not applicable
Measles-rubella
Concerning
Concerning
Concerning
Measles-mumps-rubella (MMR)2
Concerning
Concerning
Concerning
Penta (whole-cell pertussis-containing)
Healthy
Healthy
Healthy
Hexa (acellular pertussis-containing)2
Unhealthy
Unhealthy
Unhealthy
Tetanus-diphtheria2
Healthy
Healthy
Healthy
Inactivated polio vaccine, stand-alone
Healthy
Healthy
Concerning
Rotavirus
Healthy
Healthy
Concerning
Cholera
Not applicable
Not applicable
Concerning
Yellow fever
Not applicable
Not applicable
Concerning

1) No market study update in 2020 - same as 2019.

2) No market study update - same as 2020.

Definition: Level of health of the global market.
  • Healthy: The market has a diverse and stable supplier base
  • Concerning: The market has a significant concentration of vaccine supply with a potential for market disruption
  • Unhealthy: The market does not have a stable and diverse supply
Method of estimation:

Step 1) For each antigen, conduct a review and sum the number of criteria for a healthy market ‘met’ in the most recent market assessment.

The overall health of a vaccine market includes an assessment of the following criteria:

  1. Total number of suppliers
  2. Relative concentration among suppliers (market share of the two largest producers)
  3. Ability to distribute globally
  4. State of the development pipeline - the number of vaccines in phase III clinical development

Step 2) Determine the level of health based on the conditions outlined below.


2019/2020 & 2021:
  • Healthy: First three criteria are positive and the last is not negative.
  • Concerning: One of the first three criteria is negative or all of the first three criteria are neutral and the fourth is negative.
  • Unhealthy: Two or more of the first three criteria are negative.


2022:
  • Healthy: Most scores are positive across the four criteria.
  • Concerning: Most scores are neutral across the four criteria.
  • Unhealthy: Most scores are negative across the four criteria.
  • Only the first three criteria are used for assessment if information on the fourth (number of vaccines in phase III clinical development) is missing.

Limitations: Flexibility given to accommodate specific needs of different market contexts may come with additional subjectivity that may pose challenges in reaching assessment alignment.
Data source: UNICEF Supply Division, Market Information for Access (MI4A) vaccine purchase database (contains information on vaccine prices, volumnes, manufacturers, procurement modalities, contract length, and more as reported through

The IA2030 Scorecard visualizes the monitoring and evaluation indicators of the IA2030 Framework for Action endorsed in 2020 by the World Health Assembly, with the support of countries and partners. The scorecard is a collaborative effort led by MOMENTUM Country and Global Leadership working in partnership with the IA2030 Working Groups on Monitoring & Evaluation and Communications & Advocacy, with oversight from the IA2030 Secretariat and IA2030 Coordination Group (IACG). Share feedback here.

This resource is freely available for use per the Creative Commons license: Attribution 4.0 International.


Citation: Immunization Agenda (IA2030) Scorecard. scorecard.immunizationagenda2030.org. Accessed: undefined
US AID and Momemtum logos